Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of complement C3 inhibitor CP40-KK in preparation of medicine for preventing and treating pulmonary arterial hypertension

A technology of CP40-KK and pulmonary hypertension, which can be applied in drug combination, respiratory system diseases, cardiovascular system diseases, etc., and can solve problems such as unclear pathogenesis of PAH

Pending Publication Date: 2020-06-12
TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, research on the mechanism of PAH has made some progress, but the pathogenesis of PAH is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of complement C3 inhibitor CP40-KK in preparation of medicine for preventing and treating pulmonary arterial hypertension
  • Application of complement C3 inhibitor CP40-KK in preparation of medicine for preventing and treating pulmonary arterial hypertension
  • Application of complement C3 inhibitor CP40-KK in preparation of medicine for preventing and treating pulmonary arterial hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Application of CP40-KK in the preparation of drugs for preventing and treating pulmonary hypertension:

[0021] 1) Male adult SD rats (180-250 grams) were randomly divided into 4 groups: blank control group, pulmonary arterial hypertension group, CP40-KK control group and CP40-KK treatment group ( figure 1 ), the specific operation of each treatment group is as follows:

[0022] Control group: intraperitoneal injection of the same amount of normal saline (60 mg / kg) on ​​the first day;

[0023] Pulmonary hypertension group: single intraperitoneal injection of monocrotaline (MCT, 60mg / kg) on ​​the first day;

[0024] CP40-KK control group: intraperitoneal injection of the same amount of normal saline (60 mg / kg) on ​​the first day, and daily intraperitoneal injection of CP40-KK (2 mg / kg) on ​​the 15th to 28th day;

[0025] CP40-KK treatment group: single intraperitoneal injection of monocrotaline (MCT, 60mg / kg) on ​​day 1, injection of CP40-KK (2mg / kg) on ​​day 15, and d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a complement C3 inhibitor CP40-KK in preparation of a medicine for preventing and treating pulmonary arterial hypertension. The CP40-KK can induce pulmonary artery lumen reduction and tube wall thickening of a pulmonary artery hypertension model rat by inhibiting monocrotaline. Therapeutic research results show that CP40-KK has the curative effects of remarkably inhibiting pulmonary artery lumen reduction and wall thickening, reducing right ventricular systolic pressure and reducing the ratio of right ventricular weight to left ventricular plus ventricular septum weight.

Description

technical field [0001] The invention relates to the field of medicine application, in particular to the application of a complement C3 inhibitor CP40-KK in the preparation of medicines for preventing and treating pulmonary hypertension. Background technique [0002] Pulmonary arterial hypertension (PAH) is a clinical hemodynamic syndrome characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance. The important pathophysiological basis of its development is pulmonary vasoconstriction, proliferation of endothelial cells and smooth muscle cells, and in situ thrombus formation. This implies that there are perturbations in the normal relationships between vasodilators and vasoconstrictors, growth inhibitors and mitogenic factors, and antithrombotic and prothrombotic determinants. These homeostatic imbalances may be a consequence of pulmonary vascular endothelial cell dysfunction or injury. PAH can lead to right heart failure and even death directly....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/12A61P11/00A61P9/12
CPCA61K38/12A61P11/00A61P9/12
Inventor 曾和松甘小勤王洪杰
Owner TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com